Rua Life Sciences Share Discussion Threads

[bones] 19/12/2023 17:59

To my mind it’s the fallout as the settlement chaos unwinds. It’s been possible to buy cheaper than sell at times today. Let it get sorted.

I'll come back to it in the new year when it might have settled down!

[langland] 19/12/2023 17:45

I last checked about 10 minutes before close. Then it was 10.2 offered for 500k and 10.o2 bid for at least 150k. That was the most I had seen on the bid all day.

[the surgeon] 19/12/2023 17:17

I understand you can buy a million shares at 10p

[bones] 19/12/2023 14:59

Webinar thoughts:

I’m always amazed Zoom stays relevant as a business. As is true on many webinars (not just RUA), the broadcast quality sounds like Neil Armstrong’s from the moon in 1969.

Most investors seem to have lost interest. Apart from the first, the remaining questions were mine and were somewhat fishing for specifics. Not surprising most were knocked back as any talks going on with industry are not going to be for publication anyway until deals are done, if any.

The preamble was a repeat of some of the fund raising presentation summarising the businesses.

Ultimately it remains a play on what the new investors have been led to believe in persuading them to invest at this low price. A patient game.

Pretend you are an EIS investor with three years minimum to hold. Don’t expect fireworks next month! That way any announcements of note will be a pleasant occurrence…

[the surgeon] 19/12/2023 14:57

The problem is even for FDA approval on the grafts RUA hasn’t raised enough money. So any person putting up the money for a trial which is at least 3 years in length will want all the company. Bearing in mind it will cost around 6 Million and could fail to get approval. Meaning at best RUA will only get a royalty. The same goes with the heart valve which is many years away again assuming it passes the in vivo trials. So a tiny royalty there as well. Remember RUA is losing money and has a huge payroll. Maybe it can build up its elasteon business and manufacture base but that not going to bring in huge revenues. I asked Brown how his elasteon varied from the material Foldax were using. He refused to answer. So my guess it’s identical so not unique. I very nearly thought it was a punt at 11p but I am pleased I refrained bearing in mind the calibre of the management. Should new madmen come in with experience I might reconsider. Meanwhile Foldax have a valves in patients with success so I cannot see how RUA won the case. I hope I am wrong and regret not buying but having seen how inept Brown et al I am not prepared to bet on them.

[parsons4] 19/12/2023 14:57

hedgehog1 I agree, the business going forward looks good despite the fact that BB seems to be in total control !!!

[hedgehog11] 19/12/2023 14:48

That felt like a big change in tone from the previous optimism. Nothing to get excited about but the technology still sounds great. Hoping they are playing it cool! The desire to manage investor expectations shone bright!

[wageslave] 19/12/2023 13:42

No unexpected positives in the results. A lot of cheap shares now in circulation. 5p B4 20p.

[cocker] 19/12/2023 13:26

Not quite the fireworks some were expecting

[hedgehog11] 19/12/2023 11:20

Cavendish are right to disregard Vascular for now. How have ED valued it with no knowledge of any kind of deal. I recon £65M is wildly wrong and it could be in either direction (in part I don't think it ever included progress beyond grafts into elephant trunks for example, in fact I even thought its valuation was based on the Heart Valves originally). ED themselves say all they've done is halve their valuation and add a clause that they will re-evaluate when a deal is done. And stated they could be being harsh discounting it 50%! I don't think ED can walk back so easily on their methodology so they are stuck until RUA find a partner (or don't) for Vascular.
So many unknowns driving the share price, but the fightback is well underway. Hopefully Bill will be able to be open with progress on all businesses now that the raise is complete. I just hope there are no shockers.

[davisc5] 19/12/2023 11:20

Yep definately buys appearing as sells, that 120k was also a buy.

[davisc5] 19/12/2023 08:18

Flat by the looks of it

[cocker] 19/12/2023 05:53

Align with each other, one has 25p and the other 106p target and clearly we all know the latter hasn't a clue on how to value a business, in fact its amazing his bosses allow such fantasist articles to have their name attached to it. Even if there's a decent rise tomorrow, BB has totally destroyed pre rise investors, something he promised not to do, still if you hang around long enough you just might get the same treatment.

[drradcliffe] 18/12/2023 23:55

Cavendish put out a new note today as well, target remains @ 25p. Equity Research target 106p.

Edited 19/12/23.

[rotherslade1] 18/12/2023 23:27

In theory...yes.

I would expect them to try and give a bullish gloss to the presentation Tues PM.

[davisc5] 18/12/2023 22:05

Up, down or flat?

[bones] 18/12/2023 20:22

Shares suspension lifted from tomorrow morning.

[edmonda] 18/12/2023 16:30

RUA have announced its interim results ending 30 September 2023 and together with the previous trading update, strategy update and fundraising announcement, there were few surprises. With the fundraising completed our model indicates a pathway to profitability and we publish our nearer-term financial forecasts out to YE 2025. Following on from RUA’s strategy update, we have also adjusted our valuation.
In addition to the product valuation changes reflecting RUA’s strategy update, we have incorporated the cash raised and the shares issuance into our valuation. As a result, our fair value has changed from £120.3m or 542p per share to £65.5m or 106p per share.

[bones] 18/12/2023 15:58

Equity Development have updated and revised their positions in the light of the strategy changes and new shares in issue.

They’ve halved the target market cap to around £65M which makes sense as their previous ideas were based on developing and selling fully trialled vascular and heart valve businesses neither of which will now happen as RUA wants to farm the technologies out to bigger third parties (very sensibly given its size!).

In share price terms that is still over 100p a share even on over 60M shares outstanding. Still mightily ambitious…..

”….In addition to the product valuation changes reflecting RUA’s strategy update, we have incorporated the cash raised and the shares issuance into our valuation. As a result, our fair value has changed from £120.3m or 542p per share to £65.5m or 106p per share….”

[bones] 18/12/2023 15:43

So tomorrow the new shares are in the market and I am assuming the suspension lifted soon after as the new liquidity should enable the settlement blockage to be uncorked.

[hedgehog11] 18/12/2023 14:54

Directors took £80k, albeit not £20k each.